On the stock market since 2010, it operates in the world of health and science. It has 3,088 employees. Now — the numbers.
This is an established company with proven profits.
An average decline of 18% a year over the last 4 years — the most striking risk in this picture.
The gap is $3.8B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 44% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 26% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales fell about 36% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
The sales tempo runs behind the sector. Council score: 2/10.
On our five-subject report card, GNMSF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: GNMSF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.